Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics. Charles River uses label-free biosensors and other bioanalytical assays to support biochemical/biophysical characterisation of biotherapeutic […]